MedTrace Logo

Remotely Controlled Intervention for Developmental Reading and Spelling Disorders Through the Tachidino Platform

NCT04382482 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2024-03-22

No results posted yet for this study

Summary

The study aims to document the effects of the intervention system for specific reading and spelling disorders, currently in use at Scientific Institute (IRCCS) Medea as an innovative intervention model in e-health mode. The model constitutes the application of research data collected in more than fifteen years research on the causes of dyslexia and rehabilitation techniques, combined with the most advanced technologies for remotely-controlled clinical management and therapy monitoring through adaptive, self-updating algorithms.

A single group of about 80 children will be observed and their performance on reading, spelling and metaphonological tests at pre-test, post-test and follow-up (after 6 months) will be recorded in order to assess improvement (and, consequently, treatment effectiveness) and its stability. The improvements obtained in four weeks treatment will subsequently be compared with those obtained with outpatient intervention programmes of the same duration and intensity.

Conditions

  • Developmental Dyslexia
  • Developmental Spelling Disorder

Interventions

DEVICE

Tachidino

Web-platform delivering remote treatment of reading and spelling disorders through the (visual or auditory) presentation of words and sentences to be either decoded or corrected (reordering wrong letter sequences).

Sponsors & Collaborators

  • IRCCS Eugenio Medea

    lead OTHER

Principal Investigators

  • Maria L Lorusso, Ph.D. · IRCCS E. Medea

Eligibility

Min Age
7 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-20
Primary Completion
2020-12-01
Completion
2021-01-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04382482 on ClinicalTrials.gov